Does Drospirenone And Estetrol Interact with Cyp3a Inducers Moderate And Weak?
CDI records a major classification for Drospirenone And Estetrol and Cyp3a Inducers Moderate And Weak. The stored summary is: Moderate and weak CYP3A inducers may decrease DRSP exposure, potentially leading to contraceptive failure and breakthrough bleeding. The mechanism involves drsp is a cyp3a4 substrate; induction decreases drsp exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
Evidence status
A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.
Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.
Saved label reference on DailyMed. This identifier has not been checked here as support for the current claim.
- Stored CDI classification
- Major
- Management
- Confirm exact products with your pharmacist
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
DRSP is a CYP3A4 substrate; induction decreases DRSP exposure
What To Tell Your Doctor or Pharmacist
If you are taking Drospirenone And Estetrol and your doctor is considering prescribing Cyp3a Inducers Moderate And Weak (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider